ALTEOGEN Inc. (KOSDAQ:196170)
South Korea · Delayed Price · Currency is KRW 357,000
-9,000 (-2.46%)
Jun 2, 2026, 3:30 PM KST
ALTEOGEN Revenue
ALTEOGEN had revenue of 71.60B KRW in the quarter ending March 31, 2026, a decrease of -14.45%. This brings the company's revenue in the last twelve months to 203.76B, up 34.36% year-over-year. In the year 2025, ALTEOGEN had annual revenue of 215.86B with 109.87% growth.
Revenue (ttm)
203.76B
Revenue Growth
+34.36%
P/S Ratio
93.75
Revenue / Employee
1.28B
Employees
159
Market Cap
19.10T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 215.86B | 113.00B | 109.87% |
| Dec 31, 2024 | 102.85B | 6.33B | 6.56% |
| Dec 31, 2023 | 96.52B | 67.72B | 235.08% |
| Dec 31, 2022 | 28.81B | -9.94B | -25.65% |
| Dec 31, 2021 | 38.75B | -3.68B | -8.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 790.25B |
| SK bioscience | 665.42B |
| LigaChem Biosciences | 125.87B |
| HLB Co., Ltd. | 85.20B |
| Voronoi | 7.51B |
ALTEOGEN News
- 26 days ago - ALTEOGEN Q1 Net Income Declines - Nasdaq
- 2 months ago - Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics - Nasdaq
- 9 months ago - FDA Clears Merck's One-Minute Cancer Shot - Benzinga